Revenue seen at Rs50.746 million, PAT at Rs6.253 million

Result date: 19and May 2022
Recommendation: buy
Target Price: Rs5,000

Dr. Reddy’s Laboratories (Dr. Reddy’s) could experience 3% sequential revenue growth in the US in the March 2022 quarter. It captured ~13.5% market share in Vascepa during the quarter under review, up from ~9% in Dec 2021, i.e. its market share nearly tripled from ~4.5% in the June 2022 quarter. According to IU data, Dr. Reddy’s launched Vasostrict AG on February 22 and achieved a market share of approximately 8% in the Vasostrict injection vial market. This product will be key to US revenue growth in the quarter.

The company’s revenue could increase by 7%, EBITDA by 8% and profit after tax (PAT) by 15% compared to the year-ago quarter.

Important management information to monitor:
Generic API business insights
New launch pipeline
Likely total contribution of new launches
Strategy to gain market share

million rupees

March 2022 estimates

Annual change

QoQ change
Revenue 50,746 7% (5)%
EBITDA 10,915 8% (9)%
Profit after taxes 6,253 15% (12)%

Source: IIFL Research

Comments are closed.